SEC For	m 4 FORM	4 (JNITED S	STATE	s se	ECUR	ITI	ES AND	EXC	AH	NGE C	OMM	ISSION				
Check this box if no longer subject to STATEMEN							ington, D.C. 2				OMB APPROVAL						
Section obligat	this box if no id n 16. Form 4 or ions may contii tion 1(b).	Form 5	Filed pu	rsuant	to Sectio	n 16(a) of the Secu	urities Ex	xchang		JIIIF	11		verage burde sponse:	n 0.5		
1. Name and Address of Reporting Person [*] German Christopher Paul (Last) (First) (Middle) C/O RHYTHM PHARMACEUTICALS, INC.					2. Issuer Name and Ticker or Trading Symbol <u>RHYTHM PHARMACEUTICALS, INC.</u> [RYTM] 3. Date of Earliest Transaction (Month/Day/Year) 02/16/2024								Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Corporate Controller & CAO				wner specify
222 BER (Street) BOSTON	KELEY ST	LOOR 02116	4.	If Ame	endment,	Date	of Original Filed (Month/I			ay/Year)	Lin	Individual or Joint/Group Filing (Check Applicabl ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				'n	
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, inst satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												tract, instruction on 10.	on or writter	n plan t	hat is intende	ed to	
1. Title of Security (Instr. 3) 2. Transa Date						Curitie 2A. Deem Execution	ed			ed (A) or	A) or 5. Amount , 4 and Securities		Form: I		7. Nature of Indirect		
(Month/D				lonth/Day/\		if any (Month/Day/Yea		ar) Code (Ins 8) Code V			(A) oi (D)	Price	Benefici Owned F Reported Transact (Instr. 3	Following d tion(s)		str. 4)	Beneficial Ownership (Instr. 4)
		Т	able II - De (e.					uired, Dis s, options					/ Owned	-		I	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Date, Transact Code (In				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expira Date		Title	Amount or Number of Shares					
Restricted Stock Units	(1)	02/16/2024		A		7,225		(2)	(2))	Common Stock	7,225	\$0	7,225	5	D	
Stock		1	1		1	1		1	1	I				1			1

Explanation of Responses:

\$49.23

Option

(Right to Buy)

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. 3. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

(3)

5,400

/s/ Hunter Smith, Attorney-in-Fact for Christopher Paul 02/21/2024 German Date

** Signature of Reporting Person

Common

Stock

5,400

\$<mark>0</mark>

5,400

D

02/15/2034

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/16/2024

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.